MAP2K7 and pancreatic neoplasm: Combinatorial inhibition of BCL-XL with MEK signaling enhanced cell death in colorectal, lung, and pancreatic cancers bearing RAS mutations, suggesting that BCL-XL displays a synthetic lethal interaction with RAS in a context-specific manner (146).